Experts in Europe are concerned about what the global GLP-1 agonist excitement could mean for childhood obesity, which can ...

Biotech firm Ascletis Pharma said ASC47, its muscle-preserving weight loss drug candidate, could boost the efficacy of the ...

UK shoppers are the most budget-conscious in the world when it comes to wellness, says Alex Heffernan, insight manager for ...

Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future ...

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

Weight management drugs like the GLP-1 can significantly improve health outcomes, but their exorbitant prices often limit ...

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally ...

Among 77,310 adults without diabetes who began taking semaglutide after it was approved for weight loss, 40,262 (52%) were no ...

"The findings are very exciting,” said Dr. Prachi Singh at Pennington Biomedical. “This supports the growing understanding ...

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at ...

A massive Danish study reveals that despite the remarkable weight-loss benefits of semaglutide, more than half of adults ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...